The U.S. Food and Drug Administration has approved Indianapolis-based Eli Lilly's new treatment for moderate to severe eczema ...

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Eli Lilly & Co (LLY – ...

Wells Fargo analyst Mohit Bansal assigned a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of ...

Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what its prospects are for the next ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...

Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

The demand for medications like Ozempic continues to cause shortages for both those seeking weight loss and patients with ...

Eli Lilly and Company’s LLY stock has risen 21.1% in six months ... which will make up for declining sales from Trulicity.

Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Eli Lilly with a target price of $1100 ...